RxDoctor Payments Data

Todd Vogel

Vascular Surgery · Columbia, MONPI 1235215054

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Endologix LLC accounts for 73.0% of it on its own, with 24 other manufacturers making up the rest.

$52,439in general payments, 2019–2025

Across 304 payments — averaging $172.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$38K
  • Medtronic$7K
  • W. L. Gore & Associates, Inc.$4K
  • Johnson & Johnson$796
  • Veryan Medical Incorporated$619
  • Silk Road Medical, Inc.$618
  • plus $2K from 19 others
$165,825in research payments, 2019–2025

Across 14 payments — averaging $11,845 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endologix LLC$100K
  • Veryan Medical Incorporated$65K

What the payments were for

  • Consulting fees$28,85055%
  • Travel & lodging$7,03213%
  • Food & beverage$16,55732%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,439 in reported general payments places this provider in the 85th percentile of 92 vascular surgery providers in Missouri.

See all vascular surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$83,791
Medicare patients
193
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban31$8,617
ClopidogrelClopidogrel Bisulfate40$327
Prasugrel Hcl11$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$796$8,61731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 vascular surgery providers in Missouri.

Other vascular surgery in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →